What question did this study set out to answer?

This study aims to evaluate the efficacy and safety of a rosiglitazone/metformin combination versus their monotherapies in type 2 diabetes.

October 4, 2006Diabetes Obesity and Metabolism

Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

View Full Paper

Ask AI

Bookmark

Authors

JRJ RosenstockMount Sinai Hospital JRJulie A. RoodGlaxoSmithKline (United States)ACAlexander R. CobitzGlaxoSmithKline (United Kingdom)

Discussion

Member takes

Implication

Randomized trial compares effectiveness of rosiglitazone/metformin combination therapy to monotherapy in uncontrolled type 2 diabetes, suggesting improved outcomes.

Key Points

This study aims to evaluate the efficacy and safety of a rosiglitazone/metformin combination versus their monotherapies in type 2 diabetes.
468 drug-naive patients with uncontrolled type 2 diabetes were randomized to receive RSG/MET, MET, or RSG for 32 weeks.
Primary endpoint was change in glycated haemoglobin (A1c) from baseline after the treatment period.
Safety evaluations included monitoring adverse events and clinical laboratory evaluations.
RSG/MET significantly reduced A1c from 8.9% to 6.6%, greater than MET (-1.8%; p=0.0008) and RSG (-1.6%; p<0.0001).
Mean decrease in fasting plasma glucose was greatest with RSG/MET (-4.1 mmol/l) compared to MET (-2.8 mmol/l; p<0.0001) and RSG (-2.6 mmol/l; p<0.0001).
More patients in RSG/MET group achieved target A1c levels compared to MET and RSG groups.

Cite This Study

Rosenstock et al. (2006) studied this question.

synapsesocial.com/papers/6a6531ca6cc2d5eefe0e7a8b https://doi.org/10.1111/j.1463-1326.2006.00659.x

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial compares effectiveness of rosiglitazone/metformin combination therapy to monotherapy in uncontrolled type 2 diabetes, suggesting improved outcomes.

Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

Discussion

Member takes

Implication

Key Points

Cite This Study

Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider